74% Potential Upside Sparks Investor Interest
Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) is making waves in the biotechnology sector, not just for its innovative approach to cancer resistance therapies but also for its impressive potential upside. With a market capitalization of $1.17 billion and a current stock price of $12.05, Oric is attracting attention from investors eager to tap into significant growth opportunities.
Founded in 2014 and headquartered in South San Francisco, California, Oric Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing therapies designed to counteract resistance mechanisms in cancer treatment. The company’s pipeline is robust, featuring promising candidates like ORIC-114 and ORIC-944, both in Phase 1b studies….
